Hepatic and renal end-organ damage in the Fontan circulation: a report from the Australian and New Zealand Fontan Registry by Wilson, Thomas G. et al.
Accepted Manuscript
Hepatic and renal end-organ damage in the Fontan circulation: A
report from the Australian and New Zealand Fontan Registry
Thomas G. Wilson, Yves d'Udekem, David S. Winlaw, Rachael
L. Cordina, David S. Celermajer, Gavin R. Wheaton, Andrew
Bullock, Thomas L. Gentles, Robert G. Weintraub, Robert N.
Justo, Leeanne E. Grigg, Dorothy J. Radford, Winita Hardikar,
Michael Cheung, Timothy M. Cain, Padma Rao, Stephen I.
Alexander, Julian Ayer, Charlotte Verrall, Karin Du Plessis, Janina
Chapman, Kathryn Rice, Judith Barry, Diana Zannino, Ajay J.
Iyengar, The Australian and New Zealand Fontan Registry
PII: S0167-5273(18)30069-X
DOI: doi:10.1016/j.ijcard.2018.07.118
Reference: IJCA 26785
To appear in: International Journal of Cardiology
Received date: 5 January 2018
Revised date: 21 July 2018
Accepted date: 23 July 2018
Please cite this article as: Thomas G. Wilson, Yves d'Udekem, David S. Winlaw, Rachael
L. Cordina, David S. Celermajer, Gavin R. Wheaton, Andrew Bullock, Thomas L. Gentles,
Robert G. Weintraub, Robert N. Justo, Leeanne E. Grigg, Dorothy J. Radford, Winita
Hardikar, Michael Cheung, Timothy M. Cain, Padma Rao, Stephen I. Alexander, Julian
Ayer, Charlotte Verrall, Karin Du Plessis, Janina Chapman, Kathryn Rice, Judith Barry,
Diana Zannino, Ajay J. Iyengar, The Australian and New Zealand Fontan Registry ,
Hepatic and renal end-organ damage in the Fontan circulation: A report from the
Australian and New Zealand Fontan Registry. Ijca (2018), doi:10.1016/
j.ijcard.2018.07.118
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IPT
 1 
Hepatic and Renal End-Organ Damage in the Fontan Circulation: A Report from the 
Australian and New Zealand Fontan Registry 
 
Brief title: Hepatic and Renal End-Organ Damage after Fontan 
 
Authors 
Thomas G Wilson BSc, MD
a, b
, Yves d’Udekem MD, PhDa, b, c, David S Winlaw MBBS(Hons), 
MD, FRACS
d, e
, Rachael L Cordina MBBS(Hons), PhD, FRACP
e, f
, David S Celermajer MBBS, 
MSc, PhD, FRACP
e, f
, Gavin R Wheaton MBBS, FRACP
g
, Andrew Bullock MBBS, FRACP
h
, 
Thomas L Gentles MBChB, FRACP
i
, Robert G Weintraub MBBS, FRACP
a, b, j
, Robert N Justo 
MBBS, FRACP
k
, Leeanne E Grigg MBBS FRACP
l
, Dorothy J Radford MBBS, MD, FRACP
m, n
, 
Winita Hardikar MBBS, FRACP, PhD, FAASLD
o
, Michael Cheung Bsc (Hons), MBChB, 
MRCP, MD, FRACP
a,j
, Timothy M Cain MBBS, FRANZCR, MBA, FAANMS
p
, Padma Rao 
BSc (Hons), MBBS (London), MRCP (UK), FRCR (UK), FRANZCR
p
, Stephen I Alexander 
MD, MPH, FRACP
d
, Julian Ayer BSc(Med), MBBS, MIPH, FRACP, PhD
d,e
, Charlotte Verrall 
BSc(Hons)
d,
, Karin Du Plessis PhD
a
, Janina Chapman
a
, Kathryn Rice MBChB, FRACP
i
, Judith 
Barry
i
, Diana Zannino
a
, Ajay J Iyengar MBBS(Hons), BMedSci, PhD
a, b, c
, The Australian and 
New Zealand Fontan Registry 
 
Institutions and Affiliations 
a. Heart Research Group, Murdoch Childrens Research Institute, Melbourne, Australia 
b. Department of Paediatrics, Faculty of Medicine, The University of Melbourne, Victoria, 
Australia 
c. Department of Cardiac Surgery, The Royal Children’s Hospital, Melbourne, Australia 
d. The Heart Centre for Children, The Children’s Hospital at Westmead, Sydney, Australia  
e. Department of Paediatrics, University of Sydney, Sydney, Australia 
f. Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia  
g. Department of Cardiology, Women’s and Children’s Hospital, Adelaide, Australia 
h. Children’s Cardiac Centre, Princess Margaret Hospital for Children, Perth, Australia  
i. Greenlane Paediatric and Congenital Cardiac Service, Starship Children’s Hospital, 
Auckland, New Zealand  
j. Department of Cardiology, The Royal Children’s Hospital, Melbourne, Australia 
k. Queensland Paediatric Cardiac Service, Lady Cilento Children’s Hospital, Brisbane, 
Queensland, Australia 
l. Department of Cardiology, The Royal Melbourne Hospital, Melbourne, Australia 
m. Adult Congenital Heart Unit, The Prince Charles Hospital, Brisbane, Australia 
n. Faculty of Medicine, University of Queensland, Brisbane, Australia 
o. Department of Gastroenterology, The Royal Children’s Hospital, Melbourne, Australia 
p. Medical Imaging Department, The Royal Children’s Hospital, Melbourne, Australia 
 
Word Count: 3,704 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 2 
Corresponding Author 
Prof Yves d’Udekem, MD PhD 
Department of Cardiac Surgery, Royal Children’s Hospital 
Flemington Rd, Parkville VIC 3052 
Phone: +61 3 9345 5200 Fax: +61 3 9345 6001 
E-mail: yves.dudekem@rch.org.au 
 
Acknowledgements 
The authors acknowledge Aneta Kotevski’s role in project set-up as well as all the technicians, 
clinical and support staff who assisted in data acquisition.  
  
Acknowledgement of Grant Support 
This project was supported by a grant from the National Health and Medical Research Council 
(NHMRC Project Grant 1047923). The authors acknowledge support provided to the Murdoch 
Childrens Research Institute by the Victorian Government’s Operational Infrastructure Support 
Program. Yves d’Udekem is a NHMRC Clinician Practitioner Fellow (1082186).   
 
Disclosures 
All authors have approved the final version of this manuscript.  
 
Conflicts of Interest 
Yves d’Udekem is consultant for MSD and Actelion. Robert Weintraub serves on an advisory 
board for Actelion. Andrew Bullock reports consulting fees from Actelion. The remaining 
authors have nothing to disclose.  
 
 
 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 3 
Background 
Hepatic and renal dysfunction have been observed in survivors of the Fontan procedure, however 
their incidence and associated factors remain poorly defined.   
 
Methods 
A total of 152 participants from a Registry of 1,528 patients underwent abdominal ultrasound, 
transient elastography(FibroScan), serum fibrosis score(FibroTest), in vivo Tc-99m DTPA 
measurement of glomerular filtration rate(mGFR), and urine albumin-creatinine ratio(ACR).  
  
Results 
Mean age and time since Fontan were 19.8±9.3 and 14.1±7.6 years, respectively. Features 
suggestive of hepatic fibrosis were observed on ultrasound in 87/143(61%) and no patient was 
diagnosed with hepatocellular carcinoma. Fibroscan median kPa was 10 in 117/133(88%), 15 
in 75/133(56%), and 20 in 41/133(31%). Fifty-four patients(54/118, 46%) had a FibroTest 
score 0.49 (equivalent to F2 fibrosis). FibroTest score correlated with FibroScan value 
(r=0.24,p=0.015) and ACR (r=0.29,p=0.002), and patients with ultrasound features of hepatic 
fibrosis had a higher Fibroscan median kPa(19.5 vs 15.4, p=0.002). Renal impairment was 
mild(mGFR 60-89ml/min/1.73m
2
) in 46/131(35%) and moderate (mGFR 30-59 ml/min/1.73m
2
) 
in 3/131(2%). Microalbuminuria was detected in 52/139 participants (37%). By multivariable 
analysis, time since Fontan was associated with increased Fibroscan median kPa(=0.89, 95% CI 
0.54-1.25,p=0.002) and decreased mGFR(=-0.77, 95% CI-1.29--0.24,p=0.005).  
 
Conclusions 
In the second decade after Fontan hepatic and renal structure and function are abnormal in a 
significant number of patients: close to 60% have ultrasonographic evidence of structural hepatic 
abnormalities, 46% have elevated serum hepatic fibrosis scores, and 57% have either reduced 
glomerular filtration rate or microalbuminuria. Hepatic and renal function should be monitored 
for potential impacts on outcomes after Fontan completion.  
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Abbreviations 
DTPA = diethylene-triamine-pentaacetate 
NYHA = New York Heart Association 
PVP = peripheral venous pressure 
BSA = body surface area 
mGFR = measured glomerular filtration rate 
eGFR = estimated glomerular filtration rate 
ACR = albumin-creatinine ratio 
ACE = angiotensin-converting enzyme 
IVC = inferior vena cava 
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1. INTRODUCTION 
Survival and quality of life after the Fontan procedure are exceeding previous expectations[1]. 
Successive surgical modifications have improved the efficiency of the Fontan circulation while 
reducing the burden of arrhythmias[2]. The greatest unknown moving forward is how the Fontan 
physiology will affect end-organ function in the 3
rd
 and 4
th
 decades. The characteristic findings 
of systemic venous hypertension and decreased cardiac output have been linked to hepatic 
congestion, hepatic fibrosis, and hepatocellular carcinoma[3-6]. Although very little has been 
published about the incidence of renal disease amongst the Fontan population, increased levels of 
microalbuminuria and a reduction in glomerular filtration rate (GFR) have been described[7, 8]. 
The incidence of hepatic and renal dysfunction, the best methods of screening and the precise 
determinants of these changes after Fontan, however, remain largely unknown. 
 
2. METHODS 
 2.1 Patients 
Patients were recruited for this cross-sectional study from the Australian and New Zealand 
Fontan Registry, the full design and administration of which has been described previously 
[1]. Patients were eligible for recruitment if they were a minimum of 8 years of age, a minimum 
of 5 years post Fontan, had consented to participate in Registry sub-studies and could attend one 
of three study centres. The full design of the present study was approved by the national and 
local hospital ethics committees of each centre. Baseline characteristics and follow-up data were 
obtained from the Registry database [1]. History of arrhythmia was defined as either 
tachyarrhythmia (supraventricular tachycardia, atrial flutter, atrial fibrillation, or intra-atrial re-
entry tachycardia) or bradyarrhythmia (complete heart block, sinus node dysfunction, or sinus 
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bradycardia [resting HR <50 bpm]). The presence of arrhythmia was determined using 
cardiologist clinical review documentation and hospital medical documentation. The time point 
at which an arrhythmia was first recognized was recorded as the time of onset. 
 
2.2. Clinical assessment 
All participants underwent an initial clinical assessment including a targeted history and physical 
examination. Height, weight, heart rate, blood pressure, oxygen saturation, and the presence of 
jaundice, hepatomegaly, ascites or other manifestations of chronic liver disease and/or portal 
hypertension were recorded. Palpable splenomegaly was subjectively determined by the 
examining clinician on abdominal palpation. Body surface area (BSA) was calculated using 
Haycock’s formula, and functional capacity was categorized by New York Heart Association 
(NYHA) Class I-IV. The order of testing was as follows: (1) blood sampling, (2) peripheral 
venous pressure, (3) Tc-99m DTPA clearance, (4) Fibroscan, (5) abdominal ultrasound, (5) 
echocardiography.  
 
2.3. Measurement of peripheral venous pressures 
Peripheral venous pressure (PVP) was measured at the time of cannulation for Tc-99m DTPA 
clearance using a portable pressure monitor with a standard pressure transduction setup. The 
cannula was inserted in the cubital fossa or cephalic vein, and measurements were taken with 
participants lying supine. The pressure transduction circuit was connected using three 3-way taps 
with a transducer between the second and third taps from the patient. Zero pressure was levelled 
with the transducer at the level of the mid-axillary line. End-expiratory, end-inspiratory and 
pressures at rest were recorded and used to calculate a mean PVP, which was used as a surrogate 
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marker of central venous pressure[9]. 
  
2.4. Assessment of the hepatic structure and function 
Patients underwent transabdominal ultrasonography with hepatic and portal venous Doppler 
using a Siemens or Acuson S2000 ultrasound machine. Assessment of liver surface, echotexture, 
echogenicity, and sonographic features of portal hypertension were all included in the imaging 
protocol. Patients were fasted for at least 8 hours prior to imaging. Spleen length was converted 
to a percentage of the upper limit of normal based on age and gender.   
A FibroScan® (Echosens, France) was performed at the time of the clinical assessment using 
age-appropriate transducers. The FibroScan utilizes transient elastography to measure liver 
stiffness, and has been validated as a non-invasive marker of liver fibrosis[10]. A series of ten 
measurements were used to calculate a median kPa value, and these were stratified according to 
the METAVIR scoring system for stages of estimated fibrosis[11]. Cut-off values ranging from 
7.1 to 8.8kPa have been used to diagnose F2 fibrosis in patients with other etiologies of chronic 
liver disease[12]. 
Laboratory measurements were conducted on fasting venous blood samples (minimum 8 hours 
fasting) immediately prior to measurement of Tc-99m DTPA clearance. A total of 6 haemolysed 
samples were excluded from the study.  
A panel of six biochemical markers (alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, -
GT, total bilirubin and ALT) were used to calculate a FibroTest
®
 score (BioPredictive, Paris), a 
validated serum measurement of liver fibrosis[13]. Bilirubin and creatinine were used to 
calculate a MELD-XI score using the formula MELD-XI=11.76(loge creatinine) + 
5.112(loge total bilirubin)+9.44[14]. Creatinine and total bilirubin values <1 mg/dl were set to 1 
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mg/dl for the purpose of calculating the score. Creatinine was set at 4 mg/dl for patients with 
measured creatinine values >4 mg/dl.  
  
2.5. Assessment of renal function 
Measurement of GFR (mGFR) was performed using vivo Tc-99m DTPA clearance using 
multiple time point blood sampling and a single reference standard. All patients were pre-
hydrated with 20ml/kg of oral water which was consumed in the one hour preceding the study. 
Serum creatinine was measured using an enzymatic assay at two of the three centres, and by the 
Jaffe method at the other centre, and values were converted from mol/L to mg/dL for the 
purpose of eGFR calculation. An eGFR was calculated from serum creatinine using the Schwartz 
equation (0.413  (height [Ht]/serum creatinine [Scr]), with Ht in centimetres, and Scr in mg/dL) 
in children (<18 years) and the MDRD equation (175  SCr
-1.154
  age-0.203  (0.742female)  
(1.212
Black
) in adults (18 years)[15]. An early morning spot urine sample was collected to 
calculate an albumin-creatinine ratio (ACR), and microalbuminuria was defined as an ACR  
2.5mg/mmol in males and  3.5mg/mmol in females. 
 
2.6. Assessment of cardiac function 
Standard transthoracic echocardiography was undertaken using a GE Vivid 7 ultrasound machine 
with age-appropriate transducers. Chest leads were placed during the study to correlate events 
with electrocardiogram (ECG) and respiratory tracings. Participants were classified as having 
moderate/severe valve regurgitation if RV, LV, or common AV valve regurgitation was 
moderate or severe; both right and left AV valve regurgitation grades were mild; native aortic 
valve or native pulmonary valve regurgitation was moderate or severe; or both native aortic 
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valve and native pulmonary valve regurgitation grades were mild. The images were acquired and 
interpreted at each of the three centres using a standard protocol. Qualitative assessment of 
cardiac function was obtained by focused 2D and colour Doppler imaging.  
  
2.7. Statistical analysis 
Variables are presented as count (percentage), mean (standard deviation (SD) or median 
(interquartile range (IQR). Laboratory results for which different references ranges apply for 
different subgroups are reported as categorical variables (lower/within/higher than reference 
range). Laboratory measurements were included in the analysis as both absolute values and/or as 
percentages of an upper limit of normal. Correlations between normally distributed variables 
were calculated using Pearson’s correlation (r). T-tests for 2 groups or ANOVA were used to 
compare means for normally distributed variables and for non-normally distributed variables the 
Wilcoxon rank sum test for 2 groups or the Kruskal-Wallis test were used to compare medians. 
Multiple linear regression analyses were performed to identify independent variables associated 
with mGFR, FibroScan (median kPa), logarithmic transformed urine ACR and FibroTest score. 
Logistic regression analysis was performed to identify factors affecting the presence of hepatic 
fibrosis on ultrasound. Patient characteristics, including baseline clinical and surgical data 
collected in the Registry were utilized within the analyses, along with data collected as part of 
the study assessment. Variables found to be associated with the outcome in the univariable 
setting (using a threshold of p <0.05) were included in what we called a “full model”. We 
allowed up to 16 variables to be included in the “full model” and then using backward 
elimination (with a threshold of p <0.05) and taking into account collinearity among variables, 
reduced the model such that all included variables were independently associated with the 
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outcome variable using a significance level of 5%. Variables considered to be possible 
confounders (i.e. time since Fontan) were included in the final multivariable model regardless of 
their association with the outcome. Warfarin was excluded from the final multivariable model for 
Tc-99m DTPA mGFR based on clinical significance. All statistical analyses were performed in 
R (Version 3.3.2, http://www.r-project.org/). 
  
3. RESULTS 
A total of 152 patients were recruited for participation across three study centres from a total of 
1,129 patients that were assessed for eligibility (Appendix G). Patient characteristics compared 
to the total Registry population are displayed in Table 1.  
 
3.1. Clinical assessment 
Clinical features suggestive of portal hypertension and/or chronic liver disease were observed in 
35 patients (23%) at the time of the initial assessment, including hepatomegaly in 18 (12%), 
palpable splenomegaly in 11 (7%), spider naevi in 14 (9%), jaundice in 4 (3%) and ascites in 4 
(3%). Eighteen patients (12%) had clinically evident peripheral edema. Seven patients (5%) 
reported a history of hematemesis. Mean resting oxygen saturations were 944.3%. The NYHA 
status and proportion of patients taking aspirin, warfarin and angiotensin-converting enzyme 
(ACE) inhibitors are displayed in Table 1. Additional medications at the time of enrolment 
included beta blockers (23,15%), diuretics (16,11%), and digoxin (5,3%).  
 
A total of 129 patients (85%) underwent measurement of PVP at the time of the clinical 
assessment. Mean PVP was 14.3±4.6mmHg and did not differ significantly between Fontan 
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types (ECC 14.23.9 mmHg, LT 13.04.5 mmHg, and AP 14.14.9 mmHg, p=0.3), or between 
fenestrated and non-fenestrated patients (14.44.7 vs 13.73.9, p=0.4). PVP was not associated 
with increased time after Fontan (r=0.01, p=0.8).  
  
3.2. Liver assessment 
3.2.1. Abdominal ultrasound 
A total of 143 patients underwent an abdominal ultrasound. Features suggestive of hepatic 
fibrosis (parenchymal changes, heterogeneous echotexture, surface nodularity or hyperechoic 
lesions) were observed in 87 patients (61%). Liver surface nodularity was identified in 19 
patients (13%). Features suggestive of portal hypertension were observed in 41 patients (29%) 
(splenomegaly in 35, ascites in 4, and portal vein flow reversal in 3). No patient had varices 
identified on ultrasound. No discrete liver lesions suspicious of hepatocellular carcinoma (HCC) 
were demonstrated. Nine of the 11 patients (82%) identified as having palpable splenomegaly on 
clinical examination had splenomegaly on abdominal ultrasound, with the remaining two patients 
having a spleen length just below the upper limit of normal for age. After adjustment for time 
since Fontan, history of arrhythmia was associated with features of hepatic fibrosis on ultrasound 
(odds ratio (OR)=3.79, 95% CI 1.38-12.4, p=0.02). Resting oxygen saturations did not differ 
between those with or without evidence of hepatic fibrosis on ultrasound (93.85.0 vs 94.53.4, 
p=0.37). Patients with ultrasonographic evidence of portal hypertension did not have 
significantly increased mean PVP measurements compared to those without (14.25.1 vs 
13.83.8, p=0.6).  
 
3.2.2. FibroScan 
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A FibroScan was undertaken in 133 patients (88%), with a median kPa of 16.5 (11.7-21.3). 
Median kPa based on Fontan type was 18.4 (11.3-22.9), 17.0 (12.3-21.4) and 16.0 (11.5-21.1) for 
AP, LT and ECC, respectively (p=0.7). Median kPa was 10 in 117 patients (88%), 15 in 75 
(56%), and 20 in 41 (31%). Patients with clinical features suggestive of chronic liver disease 
(hepatomegaly, palpable splenomegaly, jaundice, ascites or spider naevi) had a higher median 
kPa compared to those without (19.0 (15.1–23.3) vs 15.1 (11.2–20.9), p=0.02). Higher median 
kPa was associated with a higher mean PVP (r=0.23, p=0.01).  
By multivariable analysis, increased time since Fontan was associated with a higher median kPa 
(increase of 0.84 kPa per year increase, 95% CI 0.44-1.24, p<0.001). Median kPa versus time 
since Fontan is displayed in Figure 1. After adjustment for time since Fontan, other factors 
associated with a higher median kPa were ECC Fontan type (16.4 kPa higher than AP Fontan 
type, 95% CI 8.1-24.26, p<0.001), presence of fenestration (ß=4.3, 95% CI 0.7-7.9, p=0.02) and 
history of arrhythmia (ß=5.3, 95% CI 1.3-9.3, p=0.01).  
 
3.2.3. Laboratory measurements of hepatic function (Table 2). 
A FibroTest score was generated for a total of 118 patients. Nine patients had a haptoglobin 
value below assay, and a FibroTest score was not calculated for these patients. Median FibroTest 
score was 0.46 (0.34-0.64) and 54 patients (46%) had a FibroTest score equivalent to F2 
fibrosis based on the METAVIR staging system[11]. By multivariable analysis, factors 
associated with a higher FibroTest score were male gender (ß=0.13, 95% CI 0.06-0.19, p<0.001), 
palpable splenomegaly (ß=0.16, 95% CI 0.05-0.27, p<0.01), increased serum BNP (analysed as 
log(BNP); ß=0.113 per 100 unit increase, 95% CI 0.034-0.192, p<0.01), and decreased platelet 
count (ß=-0.067 per 100 unit increase, 95% CI -0.118--0.017, p=0.01).  
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A MELD-XI score was calculated for 123 patients. Patients with a MELD-XI score >12 had a 
higher median kPa than those with a score <10 (2410.7 vs 16.77.5, p=0.02). MELD-XI score 
was higher in those with ultrasonographic features of hepatic fibrosis (10.41.8 vs 9.81.1, 
p=0.04). 
 
3.3. Kidney assessment 
3.3.1. Renal ultrasound 
Findings of increased parenchymal echogenicity were seen in 8 patients (6%), cortical thinning 
in 4 (3%), and discrete scarring in 6 (4%). Pelvicalyceal system dilatation was observed in 2 
patients (1%). One patient had a solitary kidney. Five patients (3%) had enlarged kidneys 
measured as >95
th
 centile in length.  
 
3.3.2. Measurement of GFR 
 A total of 131 patients underwent measurement of glomerular filtration rate (mGFR) by method 
of Tc-99m DTPA clearance. Three patients (2%) had an mGFR <60ml/min/1.73m
2
, 46 (35%) 
had an mGFR of 60-90ml/min/1.73m
2
, and 82 (63%) had an mGFR of >90ml/min/1.73m
2
. The 
median age of those with an mGFR <90 was 17.9 (12.3-24.7) years. Rate of decline in mGFR 
was 9.92ml/min/1.73m
2
 per decade following Fontan (Figure 1). By multivariable analysis, 
factors associated with a lower mGFR were increasing time since Fontan (ß =-0.77, 95% CI -
1.29--0.24, p=0.005), and NYHA Class III relative to NYHA Class I (ß=-22.1, 95% CI -38.0--
6.2, p<0.01).  HLHS was associated with a higher mGFR, even after adjustment for age (ß=25.6, 
95% CI 12.7-38.6, p<0.001) and time since Fontan (ß=26.4, 95% CI 13.0-39.8, p<0.001). 
The mGFR of patients who were currently taking an ACE inhibitor did not significantly differ 
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from to those who were not (101.929.2 vs 96.821.5, p=0.26). 
 
 3.3.3. Laboratory measurements of renal function (Table 2). 
Mean serum creatinine was 6017mol/L using the enzymatic method and 6414mol/L using 
the Jaffe method (p=0.2). Mean eGFR(Schwartz) in children was 158  31 mL/min/1.73m2, and 
mean eGFR(MDRD) in adults was 108  22 mL/min/1.73m2. None of the children had an 
eGFR(Schwartz) <90 mL/min/1.73m
2
. Fifteen of the 66 adult patients (23%) had an 
eGFR(MDRD) <90 mL/min/1.73m
2 
and one adult patient (2%) had an eGFR (MDRD) <60 
mL/min/1.73m
2
. There was a positive correlation between mGFR and eGFR (MDRD) (r = 0.67, 
p < 0.0001) in adults, however eGFR(Schwartz) did not correlate significantly with mGFR in the 
children (r = 0.22, p = 0.1). Bland-Altman plots comparing Tc-99m DTPA GFR (mGFR) with 
eGFR are shown in Appendix F. Both equations overestimated mGFR (eGFR (Schwartz): bias 
50.8, 95% CI 41.1-60.5 mL/min/1.73m
2
, p < 0.0001; eGFR (MDRD): bias 16.1, 95% CI 11.8-
20.4 mL/min/1.73m
2
, p <0.0001).  
A total of 52 of 139 patients (37%) had an increased ACR. Median ACR was 2.2 (1.1-3.9) and 
2.3 (1.4-4.1) for male and female patients, respectively. Higher mean PVP was associated with 
an increased ACR (r=0.18, p=0.05), however there was no significant correlation between PVP 
values and GFR (measured via Tc-99m DTPA clearance or estimated from serum creatinine). By 
multivariable analysis, factors associated with a higher log ACR were increased total serum 
bilirubin (ß=1.73 per 100-unit increase, 95% CI 0.20-3.26, p=0.03) and decreased serum 
haptoglobin (ß=-0.62, 95% CI -1.04--0.20, p<0.01). ECC Fontan type was associated with a 
lower ACR relative to AP Fontan type (ß=-1.16, 95% CI -2.17--0.14, p=0.03). There was no 
significant difference in ACR between patients taking and not taking an ACE inhibitor at the 
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time of the study (ACR elevated in 38.1% vs 37.9%, p=0.95).  
Of the 124 patients who underwent measurement of both Tc-99m DTPA clearance and urine 
ACR, 18 (15%) had both an mGFR <90 and an elevated ACR, and 71 (57%) had either an 
mGFR <90 or an elevated ACR. 
 
3.4. Echocardiographic assessment of cardiac function  
Echocardiography was performed in 142 participants (93%). Ventricular systolic function was 
mildly impaired in 19 patients (13%) and moderately impaired in 5 (4%). Atrioventricular valve 
(AVV) regurgitation was mild in 52 patients (37%) and moderate in 15 (11%). There were no 
significant associations between degree of ventricular systolic dysfunction or atrioventricular 
valve regurgitation and measurements of liver fibrosis. An increased E-A ratio was associated 
with increased median kPa (r =0.32, p<0.001) and patients with an E-A ratio >2 had a higher 
median kPa compared to those with an E-A ratio <1 (22.410.5 vs 15.15.0, p=0.02). 
Both decreased deceleration time (DT) and decreased percentage change in IVC diameter from 
inspiration to expiration were associated with an increased mean PVP (r=-0.26, p=0.006, and r=-
0.21, p=0.02, respectively).  
 
3.5. Correlations between major endpoints 
Correlations between major outcome variables are displayed in Table 3.  
 
4. DISCUSSION 
This cross-sectional study provides a detailed analysis of the determinants of hepatic and renal 
function in a representative sample of the Australian and New Zealand Fontan population. It 
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confirms the high prevalence of end-organ damage associated with the Fontan circulation [8, 16, 
17]. After a median of 14 years, close to two-thirds of patients had sonographic evidence of 
structural hepatic damage, and a significant proportion had elevated elastography measurements 
and/or serum fibrosis scores. Our data, demonstrating changes in a number of different non-
invasive markers of liver and renal damage, serves as a basis for future longitudinal studies 
defining the best predictors of Fontan failure and screening methods for end-organ damage. Our 
findings may also facilitate targeting of early interventions to prevent deterioration of the Fontan 
circulation. 
The utility of Fibroscan in Fontan associated liver disease remains controversial. We 
demonstrated an association between FibroScan values and both ultrasonographic features and 
serum-based measures of hepatic fibrosis, and therefore suspect that it may be of some use for 
estimating the degree of hepatic fibrosis in Fontan patients. The potential influence of raised 
venous pressures must be taken into account when interpreting results, however we are not 
currently in a position to define an exact method of correction based on venous pressures. 
Serological markers appear to be often only mildly deranged and may underestimate the 
magnitude of end-organ damage in some cases, however trends over time may be useful. The 
association between elevated transient elastography values and the ECC Fontan is difficult to 
understand. It could be explained by an undetected selection bias towards the more severe end of 
the single ventricle spectrum in more recent years, or alternatively, differences in stiffness and 
flow impedance in the Fontan circuitry between the ECC and earlier modifications. 
Our study is one of the first to highlight the high prevalence of renal dysfunction in this 
population, with more than half of the patients having a reduced glomerular filtration rate or 
microalbuminuria. This is consistent with the recent findings of Lee et al, which demonstrated 
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evidence of CKD in close to half of an adult-aged Fontan cohort using combined criteria based 
on mGFR and urine ACR[18]. The precise mechanisms leading to renal impairment in Fontan 
patients remain unclear, but it is possible that these changes are progressive and related to the 
physiological stress imposed by the Fontan state. Although no conclusive link has been 
established between creatinine-based eGFR and late adverse clinical events, cystatin C-based 
eGFR has been linked to adverse outcomes after Fontan[19]. This suggests that creatinine-based 
equations may inaccurately estimate true GFR in Fontan patients, which in turn may explain the 
lack of correlation between mGFR and creatinine-based eGFR in children. Creatinine-based 
GFR estimation proved more accurate in the adult patients despite a tendency to overestimate 
mGFR, although this was much less marked than seen in the children. The finding of an 
increased mGFR in HLHS patients even after adjustment for age and time since Fontan is 
surprising, however a convincing explanation for this remains elusive at this time.  
There is currently no available medical therapy to prevent end-organ damage in the Fontan 
circulation, which may lead one to question the rationale for monitoring these changes. We 
would argue that the potential for malignant transformation of hepatic lesions, as well as the 
possible impacts on eligibility for cardiac transplantation both validate the monitoring of end-
organ consequences. Based on this, and to further build on our understanding of the aetiology 
and temporality of these changes, hepatic and renal function should be followed serially in all 
patients after Fontan completion. The finding of abnormal hepatic and renal function should also, 
in some cases, prompt investigation to exclude reversible impediment to the passive pulmonary 
blood flow in the Fontan circuit in the form of thrombi, stenosis and valve regurgitation. Despite 
the fact that none of the patients in the current study had malignant hepatic lesions identified on 
imaging, we believe that the established risk of hepatocellular carcinoma warrants some form of 
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mandatory surveillance imaging of the liver. The choice of modality is likely to be influenced by 
further studies comparing a variety of non-invasive techniques with histological findings. Further 
insights into the nature and mechanisms of renal impairment in the Fontan population will aid 
the ongoing management of these patients.  
 
5. Limitations  
This study provides a cross-sectional measurement of the impact of the Fontan circulation on 
hepatic and renal function at a single time point; to more precisely evaluate the incidence of 
these issues over time, prospective repeat measurements are necessary. The lack of histological 
findings is also a limitation of this study.  
 
6. CONCLUSIONS 
In the second decade after Fontan, hepatic and renal structure and function are abnormal in a 
significant number of patients: close to two-thirds have ultrasonographic evidence of structural 
hepatic abnormalities, half have elevated serum hepatic fibrosis scores, and half have renal 
dysfunction with either reduced glomerular filtration rate or microalbuminuria. The hepatic and 
renal function of patients with a Fontan circulation should be monitored for potential impacts on 
outcomes after Fontan completion. Further studies will focus on defining the ideal methods of 
surveillance and identification of potential treatment options or strategies to alleviate end-organ 
dysfunction after the Fontan procedure.   
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Table 1. Patient characteristics 
Characteristics Participants (n 
= 152) 
Total (n 
=1,129)
 *
 
p-value 
Male, n (%) 80 (53%) 655 (58%) 0.4 
Age in years, mean (SD) 19.8 (9.3) 19.5 (10.5) 0.7 
Years post-Fontan, mean (SD) 14.1 (7.6) 13.3 (9.4) 0.2 
Anatomical comorbidities, n (%)    
   Dextrocardia/Mesocardia 16 (11%) 102 (9%) 0.4 
   Isomerism/Heterotaxy 13 (9%) 78 (7%) 0.4 
Ventricular morphology, n (%)    
 Left 103 (68%) 677 (60%) 0.1 
 Right 38 (25%) 361 (32%)  
 Biventricular/Indeterminate 11 (7%) 91 (8%)  
Primary morphological diagnosis, n 
(%) 
   
TA 39 (26%) 247 (22%) 0.1 
DILV 32 (21%) 194 (17%)  
DORV 16 (11%) 147 (13%)  
CAVC 16 (11%) 97 (9%)  
HLHS 15 (10%) 134 (12%)  
ccTGA 13 (9%) 78 (7%)  
PA-IVS 9 (6%) 89 (8%)  
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Other 12 (8%) 143 (13%)  
Prior BCPS, n (%) 111 (73%) 734 (65%) 0.05 
Age at Fontan, mean (SD) 5.7 (4.3) 5.8 (4.0) 0.99 
Fontan type, n (%)    
AP 20 (13%) 125 (11%) 0.7 
LT 31 (20%) 226 (20%)  
ECC 101 (67%) 778 (69%)  
Fenestrated
**
, n (%) 52 (34%) 406 (36%) 0.5 
Ventricular systolic dysfunction ≥ 
moderate after Fontan, n (%) 
 
14 (9%) 
 
105 (9%) 
- 
Current medications, n (%)    
ACE inhibitor 60 (39%) 406 (36%) 0.2 
Aspirin  61 (40%) 431 (38%) 0.6 
Warfarin 85 (56%) 599 (53%) 0.4 
NYHA Classification, n (%)    
I 104 (68%) 791 (70%) 0.06 
II 40 (26%) 309 (27%)  
III 8 (5%) 29 (3%)  
Pacemaker in situ, n (%) 16 (11%) 68 (6%) - 
*Includes all patients assessed for study eligibility. SD: standard deviation; TA: tricuspid atresia; 
DILV: double-inlet left ventricle; DORV: double-outlet right ventricle; CAVC: common 
atrioventricular canal; HLHS: hypoplastic left heart syndrome; ccTGA: congenitally-corrected 
transposition of the great arteries; PA-IVS: pulmonary atresia with intact ventricular septum; 
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BCPS: bidirectional cavopulmonary shunt; AP: atriopulmonary; LT: lateral tunnel; ECC: 
extracardiac conduit; ACE: angiotensin-converting enzyme; NYHA: New York Heart 
Association.  
**Fenestrated at time of Fontan operation.  
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Table 2. Laboratory results 
Parameters Median (IQR) Normal values* Number 
abnormal (%) 
Platelets (x109/L) 
 
 
192 (155-245) 150-600 26 (20%) 
Liver enzymes    
ALT (U/L) 33 (25-39) 10-40 32 (24%) 
GGT (U/L) 73 (52-112) 8-78 58 (44%) 
AST (U/L) 30 (25-37) 0-40 23 (19%) 
ALP (U/L) 64 (38-82) 30-120 8 (6%) 
AFP (ng/mL) 1.7 (1.0-2.0) 0-10 0 (0%) 
Albumin (g/L) 43 (41-46) 35-50 5 (4%) 
Total bilirubin (mol/L) 13 (10-18) 0-15 42 (32%) 
LDH (U/L) 511 (420-603) 313-618 29 (24%) 
Creatinine (mol/L) 60 (50-71) 50-110 2 (2%) 
Urea (mmol/L) 4.9 (4.1-5.8) 2.1-6.5 9 (7%) 
ALT: alanine transaminase; GGT: γ‐glutamyl‐transpeptidase; AST: aspartate transaminase; ALP: 
alkaline phosphatase; AFP: alpha-fetoprotein; LDH: lactate dehydrogenase; eGFR: estimated 
glomerular filtration rate.  
*Values with differing age-dependent ranges were adjusted to those presented above based on 
the percentage of the upper limit of normal. 
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Table 3. Pearson correlations between major outcome variables 
 
 
mGFR  
(Tc-99m DTPA 
clearance) 
FibroScan 
(median kPa) 
Urine ACR
*
 
FibroScan (median kPa)  0.00 (1)     
Urine ACR
*
 -0.15 (0.1) 0.14 (0.1)   
FibroTest score -0.03 (0.8) 0.24 (0.015) 0.29 (0.002) 
Values expressed as r (p-value). mGFR: measured glomerular filtration rate; Tc-99m: 
Technetium-99m; DTPA: diethylene-triamine-pentaacetate; ACR: albumin-creatinine ratio. 
*Log.
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Figure 1. FibroScan (median kPa) & glomerular filtration rate as measured by Tc-99m 
DTPA clearance (mGFR) vs. time since Fontan (n = 133, n = 131). 
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Appendix A. Pearson correlations between FibroScan median kPa (n = 133) and clinical, 
biochemical, echocardiographic and ultrasonographic features.   
 
 n r p value 
Platelet count 117 -0.33 <0.001 
Neutrophil count 117 -0.31 <0.001 
Systemic AVV EA ratio
*
 116 0.26 0.004 
MELD-XI score 110 0.25 0.007 
Time since Fontan (years) 133 0.21 0.01 
Age (years)
*
 133 0.24 0.006 
Body surface area 133 0.24 0.006 
Spleen length
†
 125 0.3 0.008 
HR 133 -0.24 0.01 
Total bilirubin
*
 117 0.23 0.01 
GGT
*
 117 0.22 0.01 
Peripheral venous pressure (mean)
*
 115 0.22 0.02 
Conduit VTI (mean)
*
 116 0.2 0.04 
Total protein 112 0.19 0.04 
*Log. †Spleen length as measured on abdominal ultrasonography and expressed as a percentage 
of the upper limit of normal based on age ranges.  
AVV: atrioventricular valve; HR: heart rate; IVC: inferior vena cava; GGT: γ-glutamyl 
transpeptidase; VTI: velocity time integral. 
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Appendix B. Pearson correlations between FibroTest score (n = 118) and clinical, 
biochemical, echocardiographic and ultrasonographic features.   
 
 n r p value 
Haemoglobin 113 0.33 <0.001 
Haematocrit 113 0.33 <0.001 
Platelet count 114 -0.3 0.001 
Albumin 112 0.3 0.001 
White cell count 114 -0.29 0.002 
Serum creatinine 110 0.28 0.003 
Total protein 112 0.27 0.003 
Time since Fontan (years) 118 0.23 0.01 
Age (years) 118 0.20 0.03 
Alpha-fetoprotein
*
  118 0.22 0.02 
LDH 104 0.23 0.02 
Peripheral venous pressure (mean) 108 0.22 0.02 
Neutrophil count 114 -0.22 0.02 
Serum urea 110 0.22 0.02 
Hepatic vein VTI (inspiration)
*
 96 -0.22 0.02 
AST
*
 116 0.21 0.03 
Arrhythmia, time since onset 31 0.46 0.03 
*Log. AVV: atrioventricular valve; LDH: lactate dehydrogenase; VTI: velocity time integral; 
AST: aspartate transaminase; IVC: inferior vena cava. 
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Appendix C. Pearson correlations between Tc-99m DTPA mGFR (n = 131) and clinical, 
biochemical, echocardiographic and ultrasonographic features. 
 
 n r p value 
Serum creatinine 119 -0.40 <0.001 
Age (years) 131 -0.37 <0.001 
Conduit VTI (expiration)
 *
 96 0.39 <0.001 
eGFR
^
 119 0.35 <0.0001 
Descending aorta mean gradient (mmHg)
 *
 115 0.35 0.001 
Age at BCPS (months)
 *
 95 -0.31 0.002 
Time since Fontan (years) 131 -0.29 <0.001 
Duration of shunt or band (years)
 *
 88 -0.32 0.003 
Conduit VTI (mean)
 *
 96 0.29 0.005 
Serum urea
*
 119 -0.25 0.007 
Age at Fontan (years) 131 -0.26 0.003 
Descending aorta Vmax 115 0.21 0.02 
Number of pre-Fontan procedures 131 0.19 0.03 
*Log. ^eGFR calculated using the Schwartz formula in children and the MDRD formula in 
adults. VTI: velocity time integral; eGFR: estimated glomerular filtration rate; BCPS: 
bidirectional cavopulmonary shunt; AVV: atrioventricular valve; VTI: velocity time integral.  
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Appendix D. Pearson correlations between log urine ACR (n = 139) and clinical, 
biochemical, echocardiographic and ultrasonographic features. 
 n r p value 
LDH
*
 113 0.32 <0.001 
Haptoglobin
*
 129 -0.29 0.001 
Total bilirubin
*
 133 0.27 0.002 
Peripheral venous pressure (inspiration) 121 0.24 0.01 
AST
*
 121 0.21 0.03 
Haematocrit 133 0.18 0.04 
*Log. LDH: lactate dehydrogenase; AST: aspartate transaminase. 
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Appendix E. Reduced multivariable models for major endpoints 
 Regression coefficient, β 
(standard error) 
95% CI 
for β 
p value 
(β=0) 
Tc-99m DTPA clearance (mGFR) 
(ml/min/1.73m
2
), n=131 
   
Intercept 110.1 (4.5) (101.3, 
118.9) 
<0.001 
HLHS 26.4 (6.8) (13, 
39.8) 
<0.001 
Time since Fontan (years) -0.77 (0.27) (-1.29, -
0.24) 
0.005 
Mild limitation -6.8 (4.6) (-15.7, 
2.2) 
0.14 
Moderate limitation -22.1 (8.1) (-38, -
6.2) 
0.007 
FibroScan (median kPa), n=120    
Intercept -12.7 (7.8) (-28, 2.7) 0.1 
Time since Fontan (years) 0.84 (0.21) (0.44, 
1.24) 
<0.001 
ECC Fontan type 16.4 (4.2) (8.1, 
24.6) 
<0.001 
LT Fontan type 7.8 (3.0) (1.9, 
13.8) 
0.011 
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History of arrhythmia 5.3 (2.0) (1.3, 9.3) 0.01 
Fenestration 4.3 (1.8) (0.7, 7.9) 0.02 
Mean IVC diameter
* 
(per unit 
increase) 
0.4 (0.3) (-0.3, 
1.1) 
0.2 
Urine ACR (mg/mmol)
#
, n=122    
Intercept 2.5 (0.7) (1.0, 3.9) 0.001 
Time since Fontan (per 10 years) -0.42 (0.25) (-0.92, 
0.08) 
0.1 
ECC Fontan type -1.16 (0.52) (-2.17, -
0.14) 
0.03 
LT Fontan type -0.54 (0.36) (-1.26, 
0.17) 
0.1 
Total bilirubin (per 100 units) 1.73 (0.78) (0.20, 
3.26) 
0.03 
Haptoglobin -0.62 (0.21) (-1.04, -
0.20) 
0.005 
FibroTest score, n=112    
Intercept 0.475 (0.077) (0.323, 
0.627) 
<0.001 
Time since Fontan (per 10 years) 0.032 (0.025) (-0.018, 
0.082) 
0.2 
Platelet count (per 100 units) -0.067 (0.026) (-0.119, -
0.016) 
0.01 
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Log (BNP) (per log unit increase) 0.035 (0.018) (0.000, 
0.071) 
0.05 
Male gender 0.53 (0.08) (0.37, 
0.69) 
<0.001 
Palpable splenomegaly 0.16 (0.06) (0.05, 
0.28) 
0.005 
  
*
Adjusted for body surface area (millimetres per m
2
). 
#
Log. DTPA = diethylene-triamine-
pentaacetate; mGFR = measured glomerular filtration rate; HLHS = hypoplastic left heart 
syndrome; NYHA = New York Heart Association; AP = atriopulmonary; ECC = extracardiac 
conduit; LT = lateral tunnel; ACR = albumin-creatinine ratio; BNP = brain natriuretic peptide.  
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Appendix F. Bland-Altman plots comparing Tc-99m DTPA GFR (mGFR) with eGFR 
(Schwartz) in children, and eGFR (MDRD) in adults, using bias plots showing mean bias 
and upper & lower limits of agreement. 
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Appendix G. CONSORT diagram detailing the recruitment of study participants
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Appendix H. Pathology techniques for major study parameters 
 
Parameter Sample  Processing/Storage  Assay 
AFP  Serum  Centrifuged at 5300rpm at 4oC for 
5mins. Assayed on arrival – no storage 
Chemiluminescent 
immunoassay 
Haptoglobin  Serum  Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Immunoturbidimetric or 
rate nephelometry 
Apolipoprotein 
A1 
 Serum  Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Immunoturbidimetric or 
rate nephelometry 
 LDH  Serum  Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Pyruvate to lactate multiple 
point rate reaction (dry 
slide) 
Urea  Serum Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Colorimetric – urease/NH4 
substrates 
Creatinine Serum Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Enzymatic two-point rate 
reaction 
(amidohylase/oxidase) or 
Jaffe method* 
Bilirubin Serum Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Colorimetric (end point) 
caffeine sodium benzoate 
 
ALT Serum Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Multiple point rate reaction 
with pyridoxal-5-phosphate 
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cofactor 
ALP Serum Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Multiple point rate (p-
nitrophenol substrate) 
AST Serum Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Multiple point rate reaction 
with pyridoxal-5-phosphate 
cofactor 
GGT Serum Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Multiple point rate reaction 
(glutamyl-nitroanilide 
glycylglycine substrate) 
Total Protein Serum Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Colorimetric (biuret) 
Albumin Serum Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Colorimetric (bromocresol 
green) 
BNP Serum Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Chemiluminescent 
microparticle Immunoassay 
Urine Albumin Urine Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Immunoturbimetric 
 
Urine 
Creatinine 
Urine Centrifuged at 5300rpm at 4oC for 
5mins Assayed on arrival – no storage 
Enzymatic – two point rate 
reaction 
(amidohylase/oxidase) 
*The Jaffe method was used at one of the three study centres.  
AFP: alpha-fetoprotein; LDH: lactate dehydrogenase; ALT: alanine transaminase; ALP: alkaline 
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phosphatase; AST: aspartate transaminase; GGT: γ‐glutamyl‐transpeptidase; BNP: brain 
natriuretic peptide.   
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Highlights 
- In the second decade after Fontan hepatic and renal structure and function are abnormal in a significant 
number of patients: close to 60% have ultrasonographic evidence of structural hepatic abnormalities, 46% 
have elevated serum hepatic fibrosis scores, and 57% have either reduced glomerular filtration rate or 
microalbuminuria.  
- Hepatic and renal function should be monitored for potential impacts on outcomes after Fontan 
completion.  
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